E

Epizyme Inc
F:EPE

Watchlist Manager
Epizyme Inc
F:EPE
Watchlist
Price: 559 EUR 3.33% Market Closed
Market Cap: 92.2B EUR
Have any thoughts about
Epizyme Inc?
Write Note

Epizyme Inc
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Epizyme Inc
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
E
Epizyme Inc
F:EPE
Change in Working Capital
-$19.4m
CAGR 3-Years
-52%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Change in Working Capital
-$1.9B
CAGR 3-Years
-19%
CAGR 5-Years
-7%
CAGR 10-Years
-20%
Gilead Sciences Inc
NASDAQ:GILD
Change in Working Capital
$7.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Change in Working Capital
-$612m
CAGR 3-Years
30%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Change in Working Capital
-$793.5m
CAGR 3-Years
-13%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Change in Working Capital
-$593.3m
CAGR 3-Years
28%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
No Stocks Found

Epizyme Inc
Glance View

Market Cap
94.1B EUR
Industry
Biotechnology
Economic Moat
None

Nestled in the bustling world of biotechnology, Epizyme Inc. emerged as a dynamic player within the realm of epigenetic medicine. The company carved a niche for itself by focusing on the development and commercialization of novel therapeutics that target the epigenetic regulation of gene expression. Founded with a vision to harness the power of small molecules to modulate the proteins responsible for reading and interpreting the epigenetic code, Epizyme strives to innovate therapies that can treat patients with serious unmet medical conditions, particularly in oncology. Its flagship product, Tazemetostat, received FDA approval for the treatment of certain types of lymphoma and soft tissue sarcoma. This marked a significant milestone for the company, confirming its ability to transform complex biological science into tangible, market-ready solutions. With a strategic approach centered on precision medicine, Epizyme monetizes its innovations primarily through direct sales, partnerships, and licensing agreements. The company’s revenue streams are buoyed by its collaborations with other biotechnology and pharmaceutical companies keen on leveraging Epizyme’s specialized expertise to advance their own drug development programs. Moreover, by advancing a robust pipeline of epigenetic therapies that span a variety of therapeutic areas, Epizyme positions itself to capture a growing share of the biotechnology market. Intellectual property and sophisticated R&D capabilities underpin its business model, enabling the company not only to produce groundbreaking therapies but also to secure significant market opportunities in an increasingly competitive landscape.

EPE Intrinsic Value
Not Available
E

See Also

What is Epizyme Inc's Change in Working Capital?
Change in Working Capital
-19.4m USD

Based on the financial report for Jun 30, 2022, Epizyme Inc's Change in Working Capital amounts to -19.4m USD.

What is Epizyme Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 3Y
-52%

Over the last year, the Change in Working Capital growth was -217%. The average annual Change in Working Capital growth rates for Epizyme Inc have been -52% over the past three years .

Back to Top